What is marginal zone lymphoma?
Marginal zone lymphoma (MZL) is a group of slow-growing (indolent) B-cell non-Hodgkin lymphomas. It starts in B lymphocytes, white blood cells that make antibodies, which normally sit in the outer “marginal zone” of lymphoid tissue.
There are three main types. Extranodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma) grows outside the lymph nodes, most often in the stomach. Splenic MZL mainly affects the spleen, blood and bone marrow, and nodal MZL affects the lymph nodes.
A special feature of MZL is its link with long-lasting inflammation. Infections such as Helicobacter pylori in the stomach and autoimmune diseases such as Sjogren syndrome can trigger it, and treating the infection can sometimes make the lymphoma disappear.
Most people with MZL live for many years. Some need no treatment at first, and many respond well to radiotherapy, antibiotics or antibody-based drugs.
1. How common is it?
MZL makes up about 7-8% of all non-Hodgkin lymphomas, and it is often described as the third most common type after diffuse large B-cell lymphoma and follicular lymphoma. The US Food and Drug Administration (FDA) estimates about 7,460 new cases a year in the United States.
| Feature | Details |
|---|---|
| Share of MZL by type | MALT lymphoma about 70%; splenic MZL about 20%; nodal MZL about 10% |
| Typical age | Usually diagnosed in the 60s; median age around 65-70 |
| Sex | Roughly equal overall; MALT lymphoma of the salivary gland and thyroid is more common in women |
| Most common site | Stomach, about a third of all MALT lymphomas |
| Other common sites | Eye area (ocular adnexa), salivary glands, lung, skin, thyroid, breast, small bowel |
| Children | Rare; paediatric nodal MZL is a separate, very indolent type, mostly in boys |
2. Types of marginal zone lymphoma
The 5th edition of the WHO classification of haematolymphoid tumours (2022) recognises the following types.
| Type | Where it grows | Typical features |
|---|---|---|
| Extranodal MZL of MALT | Stomach, eye area, salivary glands, lung, thyroid, bowel, breast | Often localised; linked with chronic infection or autoimmune disease |
| Primary cutaneous MZL | Skin | Now listed as its own type; red or purple bumps on the trunk or arms; excellent outlook |
| Splenic MZL | Spleen, bone marrow, blood | Enlarged spleen, low blood counts, lymphoma cells in the blood |
| Nodal MZL | Lymph nodes | Enlarged nodes without involvement outside the nodes or spleen |
| Paediatric nodal MZL | Lymph nodes of the head and neck | Young people; usually localised and rarely relapses after removal |
When an MZL contains sheets of large cells, it is reclassified as diffuse large B-cell lymphoma and treated as an aggressive lymphoma.
3. Causes and risk factors
MZL often develops in tissue that has been inflamed for years. Constant stimulation of B cells by an infection or an autoimmune process makes them divide repeatedly, and over time a cell can pick up genetic damage and grow out of control.
3.1 Infections and autoimmune diseases
| Trigger | Linked type | Notes |
|---|---|---|
| Helicobacter pylori | Gastric MALT lymphoma | Found in most cases; eradicating it can cure early disease |
| Chlamydia psittaci | MALT lymphoma of the eye area | Association varies widely between countries; strongest in Italy |
| Borrelia burgdorferi (Lyme disease) | MALT lymphoma of the skin | Reported mainly in parts of Europe |
| Campylobacter jejuni | Immunoproliferative small intestinal disease (IPSID) | A MALT lymphoma of the small bowel, seen mainly in young adults in the Middle East and Mediterranean region |
| Hepatitis C virus | Splenic and nodal MZL | Antiviral treatment can lead to remission |
| Sjogren syndrome | MALT lymphoma of salivary glands | Greatly increased risk compared with the general population |
| Hashimoto thyroiditis | MALT lymphoma of the thyroid | Long-standing thyroid inflammation |
3.2 Genetic changes
Several genetic changes help pathologists confirm the diagnosis and can predict response to treatment.
| Change | Where it is found | Why it matters |
|---|---|---|
| t(11;18)(q21;q21), BIRC3::MALT1 | Gastric and lung MALT lymphoma | Predicts poor response to H. pylori eradication; often found in H. pylori-negative cases |
| t(14;18)(q32;q21), IGH::MALT1 | Eye area, salivary gland, liver, skin | Switches on the same NF-kB growth pathway |
| t(1;14) and t(3;14) | Various MALT sites | Involve BCL10 and FOXP1; rare |
| Trisomy 3 and 18 | All types | Common, supportive of the diagnosis |
| Loss of 7q; NOTCH2 and KLF2 mutations | Splenic MZL | Typical of the splenic type |
| KMT2D, PTPRD and NOTCH2 mutations | Nodal MZL | Help separate it from other low-grade lymphomas |
MZL rarely carries the MYD88 L265P mutation, which helps distinguish it from lymphoplasmacytic lymphoma (Waldenstrom macroglobulinaemia).
4. How does it look?
MZL is often hidden inside the body. When it can be seen or felt, its appearance depends on the type and site.
4.1 On the outside of the body
- Eye area: a painless, soft, salmon-pink patch on the white of the eye or inside the eyelid, or a swelling of the eyelid or around the eye.
- Salivary glands: a painless, slowly enlarging swelling in front of the ear (parotid gland) or under the jaw.
- Skin: single or multiple red to purple bumps or plaques, usually on the trunk or arms, that do not itch much.
- Lymph nodes: painless, rubbery lumps in the neck, armpit or groin.
- Spleen: a large spleen may cause a visible swelling or fullness under the left ribs.
4.2 On endoscopy and scans
In gastric MALT lymphoma, the stomach lining may look red, thickened or nodular, or show shallow ulcers or erosions. The changes can look very similar to ordinary gastritis, so multiple biopsies are needed.
CT scans may show a thickened stomach wall, enlarged lymph nodes, a lung mass or patchy shadow, or a very large spleen. MZL usually takes up only modest amounts of tracer on PET-CT, and a strongly active area raises the possibility of transformation to a more aggressive lymphoma.
4.3 Under the microscope
The lymphoma consists of small to medium-sized B cells that often have pale cytoplasm (monocytoid cells), mixed with plasma cells. In MALT lymphoma, tumour cells invade and damage glands, forming lymphoepithelial lesions, and may colonise existing lymphoid follicles.
| Marker | Usual result in MZL | Why it is tested |
|---|---|---|
| CD20, CD79a | Positive | Confirms a B-cell lymphoma |
| CD5 | Usually negative | Helps exclude mantle cell lymphoma and CLL |
| CD10, BCL6 | Negative | Helps exclude follicular lymphoma |
| Cyclin D1 | Negative | Excludes mantle cell lymphoma |
| CD43 | Positive in a proportion | Supports a lymphoma rather than inflammation |
| IgD | Usually positive in splenic MZL, usually negative in MALT lymphoma | Helps tell subtypes apart |
| Ki-67 | Usually low | Reflects slow growth; a high value raises concern for transformation |
Tests showing that the B cells are all from the same clone (light chain restriction or immunoglobulin gene rearrangement) help separate lymphoma from reactive inflammation.
5. Symptoms
Many people have few or no symptoms, and MZL is sometimes found by chance on a scan, blood test or endoscopy. When symptoms occur, they depend on the type and site.
| Type or site | Common symptoms |
|---|---|
| Stomach (gastric MALT) | Indigestion, upper abdominal pain, nausea, feeling full quickly; less often vomiting, black stools or anaemia from bleeding |
| Eye area | Pink patch on the eye, eyelid swelling, watery or irritated eye, bulging eye or double vision |
| Salivary glands | Painless swelling of a gland, dry mouth (often from Sjogren syndrome) |
| Lung | Cough, breathlessness or chest infections; often found on an X-ray with no symptoms |
| Thyroid | Swelling in the front of the neck, pressure when swallowing |
| Skin | Red or purple bumps or patches |
| Small bowel | Diarrhoea, abdominal pain, weight loss |
| Splenic MZL | Discomfort or fullness under the left ribs, early fullness when eating, tiredness from anaemia, bruising or infections from low blood counts |
| Nodal MZL | Painless swollen lymph nodes |
B symptoms
Fever, drenching night sweats and unexplained weight loss of more than 10% of body weight over 6 months are called B symptoms. They are uncommon in MZL; when they appear, doctors check for progression or transformation.
Some people with splenic MZL have a small amount of abnormal antibody (paraprotein) in the blood or autoimmune problems such as autoimmune anaemia.
When to see a doctor
See a doctor if you have indigestion or stomach pain that lasts for more than a few weeks, especially after the age of 55 or with weight loss, vomiting or black stools. A painless lump that keeps growing, a pink patch on the eye, or ongoing tiredness with bruising or frequent infections should also be checked.
6. Diagnosis
A biopsy is always needed, and the tissue should be reviewed by an expert haematopathologist.
| Test | Purpose |
|---|---|
| Biopsy | Endoscopic biopsies for the stomach; removal of a whole lymph node where possible; core or excision biopsy for other sites |
| H. pylori tests | On stomach biopsies, plus breath or stool tests if biopsies are negative |
| FISH for t(11;18) | In gastric MALT lymphoma, to predict whether antibiotics are likely to work |
| Blood tests | Full blood count, LDH, kidney and liver function, protein electrophoresis, hepatitis B, hepatitis C and HIV tests |
| Blood flow cytometry | Detects lymphoma cells in the blood, typical of splenic MZL |
| CT of chest, abdomen and pelvis | Staging; PET-CT is used in selected cases or if transformation is suspected |
| Endoscopic ultrasound | Shows how deep gastric lymphoma reaches and whether nearby nodes are involved |
| Bone marrow biopsy | Usually done in splenic MZL and when systemic treatment is planned |
| Site-specific tests | MRI of the orbit, eye examination, thyroid ultrasound or lung tests as needed |
Hepatitis B testing is essential before rituximab, which can reactivate a past hepatitis B infection.
7. Staging and prognostic scores
7.1 Stage
Most nodal and extranodal MZL is staged with the Lugano classification, which replaced the older Ann Arbor system. Gastric lymphomas are often staged with the Lugano 1994 system for gastrointestinal lymphoma, which is designed for the gut.
| Stage | Description |
|---|---|
| I | One lymph node group, or one extranodal organ without node involvement (IE) |
| II | Two or more node groups on the same side of the diaphragm, or an extranodal organ with nearby nodes (IIE) |
| III | Nodes on both sides of the diaphragm, or nodes above the diaphragm with the spleen involved |
| IV | Wider spread to organs outside the lymph system, such as bone marrow, liver or lung, beyond what counts as IE or IIE |
Most MALT lymphomas are stage I or II at diagnosis. Splenic MZL almost always involves the bone marrow, so it is technically advanced, but it is still usually slow-growing.
7.2 Prognostic scores
The MALT-IPI uses three factors: age 70 or older, stage III or IV, and a raised LDH. In the IELSG-19 trial population, 5-year event-free survival was 70%, 56% and 29% for people with 0, 1, or 2 or more factors.
For all types, disease that progresses within 24 months of first treatment (POD24) carries a worse outlook. In one study, 3-year overall survival was 53% with POD24 and 95% without it.
8. Treatment
Treatment depends on the type, site and stage, on symptoms and on the person’s general health. Because MZL grows slowly, the aim is to control it for as long as possible with the fewest side effects.
8.1 Watch and wait
People without symptoms, especially with splenic or nodal MZL and normal blood counts, are often monitored without treatment (active monitoring). There is no evidence that starting treatment early in this situation helps people live longer.
Treatment is started when there are symptoms, a growing mass, falling blood counts, a large painful spleen, or a threat to the function of an organ.
8.2 Treating the trigger
| Situation | Treatment | Expected result |
|---|---|---|
| Gastric MALT lymphoma, H. pylori positive | Antibiotics plus an acid-reducing drug, regardless of stage | Remission in most localised cases; about half by 3 months, others after 12-18 months; less likely with t(11;18) |
| Gastric MALT, H. pylori negative | Antibiotics may still be tried | Response in a minority; radiotherapy is often needed |
| Eye-area MALT lymphoma | Doxycycline in some centres | Durable remission in almost half in published series, mostly from Italy |
| Hepatitis C-related MZL | Antiviral treatment | Remission in about 40-60% when the virus is cleared |
| Skin MZL with Borrelia | Antibiotics | Response in some patients |
After H. pylori treatment, repeat endoscopies with biopsies are done to confirm that the infection is gone and to check the lymphoma. If tumour cells persist without symptoms or growth, many doctors simply continue monitoring.
8.3 Radiotherapy
Radiotherapy is the standard curative treatment for localised MALT lymphoma that does not respond to antibiotics and for most stage I-II nodal MZL. Usual doses are low, around 24-30 Gy in 12-15 daily treatments, and side effects are mild.
For the eye area, and for some patients with stomach lymphoma, very low doses of about 4 Gy are being used, with further treatment if needed. Local control rates with radiotherapy are above 90% in many series.
8.4 First drug treatment for advanced or symptomatic disease
| Treatment | How it is given | Key facts |
|---|---|---|
| Rituximab alone | Intravenous or under-the-skin infusions | Mild side effects; preferred first treatment for many people with splenic MZL |
| Rituximab plus chlorambucil | Infusions plus tablets | In IELSG-19, 5-year event-free survival 68% versus about 50% with either drug alone; overall survival about 90% in all arms |
| Bendamustine plus rituximab (BR) | Infusions over 2 days every 4 weeks | Widely used for advanced disease; high response rates; lowers immunity for a long time |
| R-CVP or R-CHOP | Infusions every 3 weeks | Alternatives; R-CHOP mainly when transformation is suspected |
| Rituximab maintenance | Every 2-3 months for up to 2 years | Can lengthen remissions but has not been shown to lengthen life |
8.5 Relapsed disease
| Treatment | Type of drug | Status and evidence |
|---|---|---|
| Zanubrutinib | BTK inhibitor tablet | FDA accelerated approval (2021) and EU approval (2022) after at least one anti-CD20 treatment; MAGNOLIA trial response rate 68%, 71% progression-free at 2 years |
| Lenalidomide plus rituximab | Immune-modulating tablet plus antibody | FDA approved in 2019 for previously treated MZL, based on the AUGMENT trial |
| Ibrutinib | BTK inhibitor tablet | Active in MZL, but the US MZL approval was withdrawn in 2023 because the confirmatory trial did not support full approval |
| Lisocabtagene maraleucel (liso-cel) | CD19 CAR T-cell therapy | FDA approved in December 2025 after at least two prior lines; 95% response and 62% complete response in the TRANSCEND FL MZL cohort |
| Bispecific antibodies | CD20xCD3 antibodies | Promising results; mainly within clinical trials for MZL |
| Repeat chemoimmunotherapy or radiotherapy | Various | Often effective if the first remission was long |
The PI3K inhibitor umbralisib, once approved for relapsed MZL in the US, was withdrawn in 2022 because of safety concerns. Availability of all these treatments differs between countries.
8.6 Splenic MZL
Splenic MZL that needs treatment is usually treated first with rituximab alone, which shrinks the spleen and improves blood counts in most people. Removal of the spleen (splenectomy) is an alternative for people who cannot have rituximab, and it can bring long remissions.
People who have had their spleen removed need vaccinations against pneumococcus, meningococcus and Haemophilus, and should seek urgent care for any fever.
8.7 Transformation
Fewer than 10% of people with MZL develop transformation to diffuse large B-cell lymphoma. Warning signs include rapid growth of a lump, B symptoms and a rising LDH, and a new biopsy is needed to confirm it. Transformed disease is treated like large B-cell lymphoma, usually with R-CHOP.
9. Prognosis
MZL is usually a chronic disease that can be controlled for many years. Localised MALT lymphoma treated with antibiotics or radiotherapy is often cured, while advanced disease tends to come back after treatment but usually responds again.
| Type | 5-year relative survival (US SEER data, 1995-2009) |
|---|---|
| MALT lymphoma | About 89% |
| Splenic MZL | About 80% |
| Nodal MZL | About 77% |
Survival in MALT lymphoma also depends on the site. Eye, skin and thyroid lymphomas have the best outlook, while those in the gut and lung carry a slightly higher risk. Many people with MZL are older and die of other causes rather than lymphoma, and survival has improved since these figures were collected.
10. Follow-up and living with MZL
10.1 Follow-up
- Regular check-ups with examination and blood tests, usually every 3-6 months for the first years, then less often
- Repeat endoscopy with biopsies after treatment of gastric MALT lymphoma, at first every few months and later yearly
- Scans only when symptoms or examination findings suggest a change
- Long-term follow-up, because MZL, especially MALT lymphoma outside the stomach, can return many years later, sometimes at a different site
10.2 Everyday life
- Keep vaccinations up to date, including flu and pneumococcal vaccines; avoid live vaccines during and soon after treatment.
- Report fever, persistent cough or other signs of infection quickly, especially after rituximab, bendamustine or BTK inhibitors.
- Make sure the H. pylori infection stays cleared; reinfection is uncommon but possible.
- People with Sjogren syndrome or hepatitis C should continue regular care for these conditions.
- Living with a slow-growing lymphoma can be stressful even without treatment; lymphoma charities and support groups can help.
Resources
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Zucca, E. et al. (2020) ‘Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 31(1), pp. 17-29.
- Wotherspoon, A.C. et al. (1993) ‘Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori’, The Lancet, 342(8871), pp. 575-577.
- Olszewski, A.J. and Castillo, J.J. (2013) ‘Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database’, Cancer, 119(3), pp. 629-638.
- Thieblemont, C. et al. (2017) ‘A MALT lymphoma prognostic index’, Blood, 130(12), pp. 1409-1417.
- Zucca, E. et al. (2017) ‘Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy’, Journal of Clinical Oncology, 35(17), pp. 1905-1912.
- Leonard, J.P. et al. (2019) ‘AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma’, Journal of Clinical Oncology, 37(14), pp. 1188-1199.
- Opat, S. et al. (2023) ‘Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study’, Blood Advances, 7(22), pp. 6801-6811.
- Palomba, M.L. et al. (2026) ‘Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study’, The Lancet, 407(10532), pp. 963-975.
- National Cancer Institute (2026) Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/indolent-b-cell-lymphoma-treatment-pdq (Accessed: October 2026).
- U.S. Food and Drug Administration (2025) FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-marginal-zone-lymphoma (Accessed: October 2026).
- U.S. Food and Drug Administration (2026) Withdrawn: cancer accelerated approvals. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals (Accessed: October 2026).
Prepared by the editorial team, October 2026.